Kiniksa Pharmaceuticals Ltd reports results for the quarter ended in September - Earnings Summary

Kiniksa Pharmaceuticals International

01/11/2022 13:02

* Kiniksa Pharmaceuticals Ltd  KNSA.OQ  reported quarterly
adjusted earnings of $3.18​​ per share for the quarter ended in
September. The mean expectation of four analysts for the quarter
was for earnings of 78 cents per share.
    * Revenue rose 176.3% to $33.42 million from a year ago;
analysts
expected $93.64 million. 
    * Kiniksa Pharmaceuticals Ltd's reported EPS for the quarter
was
$3.18​.
    * The mean earnings estimate of analysts had risen by
about 298.1%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Kiniksa Pharmaceuticals Ltd shares had fallen by 11.1%
this
quarter and lost 3.0% so far this year.
    * The company reported quarterly net income of $225.09
million.
    * Wall Street's median 12-month price target for Kiniksa
Pharmaceuticals Ltd is $22.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
1 at 01:02 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      0.78           3.18           Beat
 Jun. 30 2022      -0.44          -0.29          Beat
 Mar. 31 2022      -0.41          -0.36          Beat
 Dec. 31 2021      -0.42          -0.53          Missed